Soligenix, Inc.
Soligenix is a late-stage biopharmaceutical company dedicated to developing and commercializing products to treat rare diseases with unmet medical needs. The company focuses on specialized biotherapeutics for orphan diseases and public health solutions for military and civilian applications, including vaccines and therapeutics for ricin exposure, Ebola, Marburg, and COVID-19. With expertise in orphan and unmet medical need indications, Soligenix conducts all of its Phase 2 and 3 clinical studies personally, ensuring high data quality and streamlined timelines.
Industries
Nr. of Employees
small (1-50)
Soligenix, Inc.
Princeton, New Jersey, United States, North America
Products
Topical photodynamic therapy for cutaneous T‑cell lymphoma (early-stage)
Visible‑light activated topical photodynamic therapy formulation evaluated in randomized Phase 3 studies for early‑stage cutaneous T‑cell lymphoma.
Topical therapy development for mild‑to‑moderate plaque psoriasis
Topical dermatologic therapeutic candidate for plaque psoriasis evaluated in the company pipeline.
Innate defense regulator immunomodulator for oral mucositis
Peptide‑based innate defense regulator technology developed to modulate host responses and reduce infection and mucositis in chemotherapy and radiation settings; progressed through preclinical studies and Phase 1 clinical testing.
Thermostable subunit vaccine for ricin exposure (thermostabilized formulation)
Subunit vaccine antigen formulations engineered for thermal stability and protective immunity in animal inhalational and systemic ricin exposure models.
Thermostabilization platform for vaccines
Platform technology for heat stabilization of vaccines to maintain epitope integrity and facilitate distribution without strict cold‑chain requirements.
Therapeutic candidates targeting bacterial infections and antibiotic resistance
Preclinical and early clinical therapeutic programs targeting antibiotic‑resistant and emerging bacterial infections.
Topical photodynamic therapy for cutaneous T‑cell lymphoma (early-stage)
Visible‑light activated topical photodynamic therapy formulation evaluated in randomized Phase 3 studies for early‑stage cutaneous T‑cell lymphoma.
Topical therapy development for mild‑to‑moderate plaque psoriasis
Topical dermatologic therapeutic candidate for plaque psoriasis evaluated in the company pipeline.
Innate defense regulator immunomodulator for oral mucositis
Peptide‑based innate defense regulator technology developed to modulate host responses and reduce infection and mucositis in chemotherapy and radiation settings; progressed through preclinical studies and Phase 1 clinical testing.
Thermostable subunit vaccine for ricin exposure (thermostabilized formulation)
Subunit vaccine antigen formulations engineered for thermal stability and protective immunity in animal inhalational and systemic ricin exposure models.
Thermostabilization platform for vaccines
Platform technology for heat stabilization of vaccines to maintain epitope integrity and facilitate distribution without strict cold‑chain requirements.
Therapeutic candidates targeting bacterial infections and antibiotic resistance
Preclinical and early clinical therapeutic programs targeting antibiotic‑resistant and emerging bacterial infections.
Services
Clinical development and trial conduct
Full-service conduct of Phase 2 and Phase 3 clinical studies with site engagement, specialized recruitment and protocol execution.
Project management and regulatory affairs services
In-house project management and regulatory coordination to support development programs, filings and interactions with regulatory authorities.
Government contract and grant program execution
Management of government‑funded R&D programs for biodefense and infectious disease applications, including compliance with agency requirements.
Scientific advisory board engagement
Access to and coordination of disease‑specific scientific advisory boards to inform clinical strategy and endpoint selection.
Clinical development and trial conduct
Full-service conduct of Phase 2 and Phase 3 clinical studies with site engagement, specialized recruitment and protocol execution.
Project management and regulatory affairs services
In-house project management and regulatory coordination to support development programs, filings and interactions with regulatory authorities.
Government contract and grant program execution
Management of government‑funded R&D programs for biodefense and infectious disease applications, including compliance with agency requirements.
Scientific advisory board engagement
Access to and coordination of disease‑specific scientific advisory boards to inform clinical strategy and endpoint selection.
Expertise Areas
- Clinical trial management
- Rare disease and orphan drug development
- Vaccine development and thermostabilization
- Photodynamic topical therapies for dermatology
Key Technologies
- Topical photodynamic therapy (visible-light activated)
- Innate defense regulator peptides (immunomodulatory peptides)
- Vaccine thermostabilization and lyophilization
- Subunit / recombinant vaccine antigens